Wouters W, van Dun J, Dillen A, Coene M C, Cools W, De Coster R
Department of Endocrinology and Oncology, Janssen Research Foundation, Beerse, Belgium.
Cancer Res. 1992 May 15;52(10):2841-6.
Liarozole is a new imidazole derivative with antitumoral properties. Effects of the compound alone and in combination with all-trans-retinoic acid on proliferation of MCF-7 human breast cancer cells were examined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Following 9 days of drug exposure, MCF-7 cell growth was concentration dependently inhibited by all-trans-retinoic acid (drug concentration resulting in 50% growth inhibition, 2 x 10(-8) M), while liarozole at 10(-5) M inhibited cell growth by only 35%. When MCF-7 cells were incubated with a combination of all-trans-retinoic acid and liarozole, the antiproliferative effect of all-trans-retinoic acid was clearly enhanced. This enhancement was dependent on the liarozole concentration and was more than 10-fold. A combination of 10(-8) M all-trans-retinoic acid and 10(-6) M liarozole resulted in a greater antiproliferative effect than that obtained with 10(-7) M all-trans-retinoic acid alone. When MCF-7 cells were incubated for 4 h with [3H]all-trans-retinoic acid, the radioactivity in the supernatant consisted of unaltered retinoid. However, when cells had been pretreated with 10(-6) M all-trans-retinoic acid overnight, they were able to substantially metabolize [3H]all-trans-retinoic acid during a subsequent 4-h incubation. High-performance liquid chromatography analysis of the supernatants revealed that the reaction products consisted mainly of very polar metabolites. Liarozole inhibited the metabolism of all-trans-retinoic acid in MCF-7 cells with 10(-5) M liarozole reducing the amount of polar metabolites by 87%. It is concluded that the enhancement by liarozole of the antiproliferative effects of retinoic acid on MCF-7 human breast cancer cells is probably due to inhibition of retinoic acid metabolism. Further research into these effects in MCF-7 cells as well as in other cancer cell lines will provide more information concerning the exact mechanism of action of liarozole and the use of inhibitors of retinoid metabolism in cancer treatment.
来罗唑是一种具有抗肿瘤特性的新型咪唑衍生物。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基-2H-四唑溴盐检测法,研究了该化合物单独以及与全反式维甲酸联合使用对MCF-7人乳腺癌细胞增殖的影响。药物暴露9天后,全反式维甲酸(导致50%生长抑制的药物浓度为2×10⁻⁸ M)对MCF-7细胞生长具有浓度依赖性抑制作用,而10⁻⁵ M的来罗唑仅抑制细胞生长35%。当MCF-7细胞与全反式维甲酸和来罗唑联合孵育时,全反式维甲酸的抗增殖作用明显增强。这种增强依赖于来罗唑的浓度,且超过10倍。10⁻⁸ M全反式维甲酸与10⁻⁶ M来罗唑联合使用产生的抗增殖作用比单独使用10⁻⁷ M全反式维甲酸更强。当MCF-7细胞与[³H]全反式维甲酸孵育4小时后,上清液中的放射性由未改变的类视黄醇组成。然而,当细胞用10⁻⁶ M全反式维甲酸预处理过夜后,它们在随后4小时的孵育过程中能够大量代谢[³H]全反式维甲酸。上清液的高效液相色谱分析表明,反应产物主要由极性很强的代谢物组成。来罗唑抑制MCF-7细胞中全反式维甲酸的代谢,10⁻⁵ M的来罗唑可使极性代谢物的量减少87%。得出的结论是,来罗唑增强维甲酸对MCF-7人乳腺癌细胞的抗增殖作用可能是由于抑制了维甲酸的代谢。对MCF-7细胞以及其他癌细胞系中这些作用的进一步研究将提供更多关于来罗唑确切作用机制以及类视黄醇代谢抑制剂在癌症治疗中应用的信息。